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of our method for measuring clinical disintegration time. The clini-
cal disintegration time of the 17 ODT products was between 17.6 
and 33.8 seconds in the clinical trial conducted with healthy adult 
volunteers. In the measurement of the amounts of water required for 
ingesting CTs and ODTs, no significant difference was observed in 
the amount of water required for ingesting CTs and ODTs among 
the 3 groups. The amount of water required for ingesting ODTs was 
significantly lesser than that required for ingesting CTs.
Conclusion: This study demonstrates that all the tested products, 
which are clinically available in Japan, exhibit good disintegration 
and that the disintegration time varies by the product. This study 
also showed that the amount of water required for ingesting ODTs 
is lower than that required for ingesting CTs.
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Introduction: Patients admitted to internal medicine wards receive 
a large number of drugs and are at risk of drug-related problems 
(DRPs) that may be associated with morbidity and mortality. In a 
French study, the in-hospital incidence rate of adverse drug reactions 
in internal medicine was 10.1 per 1000 patient-days and 80% of 
them could be considered preventable. The aim of the present study 
was to detect suboptimal drug use in 2 pilot wards of a general 
internal medicine service and to offer a pharmacologic and pharma-
ceutical evaluation to improve drug prescription.
Patients (or Materials) and Methods: This was a prospective study 
conducted during 6 months in 2 internal medicine wards in a 2000-
bed university hospital. Physician rounds were attended once every 
other week in each ward by a clinical pharmacist and a clinical 
pharmacologist. All patients met during the physician rounds were 
included. Prescriptions were analyzed through an assessment grid to 
detect DRPs. Treatment optimizations were suggested to prescrib-
ers during the round. The main outcome measures were: (1) most 
frequent DRPs and involved drugs or drug classes; (2) types of inter-
vention required: no intervention, verbal suggestion of treatment 
optimization, or specialized written consultation; and (3) acceptance 
rate by prescribers.
Results: A total of 145 patients (mean age, 68 [21–99]; 48% female) 
were included with 1523 prescriptions (mean, 10.6 [0–21] prescrip-
tions per patient). A total of 383 DRPs were identified (mean, 2.6 
[0–12] DRPs per patient). The most frequently identified DRPs were: 
(1) drug interactions (21%); (2) untreated indications (18%); (3) 
overdosage (16%); and (4) drug used without a valid indication 
(10%). The most frequently involved drugs or drug classes were: (1) 
for drug interactions: tramadol, antidepressants, and acenocoumarol; 
(2) for untreated indications: calcium-vitamin D, statins, and aspirin; 
(3) for overdosage: proton pump inhibitors and paracetamol; and (4) 
for drug used without a valid indication: proton pump inhibitors and 
aspirin. Fifty-one percent of the identified DRPs were considered as 
clinically not relevant and were not reported to the prescribers, 42% 
were reported with a verbal suggestion of treatment optimization, 
and 7% were considered as complex and triggered a specialized writ-
ten consultation by a clinical pharmacologist. Suggestions of treat-
ment optimization were accepted by prescribers in 84% of cases. 
Accepted suggestions were applied by physicians in 64% of cases.
Conclusion: The most frequently identified DRPs were drug interac-
tions. One half of the identified DRPs required a suggestion of treat-
ment optimization, which was accepted and applied by prescribers 
in most cases.
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Introduction: The Drug Burden Index (DBI), a novel pharmacologic risk 
assessment tool that measures an individual’s total exposure to anticho-
linergic and sedative medicines, has been associated with impaired physi-
cal function, falls, and increased hospitalization in older adults. Aims: (1) 
To develop software which calculates and generates reports on DBI; (2) 
to use published case study data to test the DBI software for accuracy; 
and (3) to test the software for usability and functionality.
Patients (or Materials) and Methods: Microsoft Access 2010 was 
used to build and design The DBI Calculator©. Twenty-five drug regi-
mens from patient case studies published in the Australian Journal 
of Pharmacy (August 2010 to August 2012) were used to compare 
DBI scores computed using The DBI Calculator© and those com-
puted manually (gold standard). Cohen’s Kappa statistics were used 
to calculate the degree of concordance between manual and auto-
mated DBI scores. Ten pharmacists accredited to perform medication 
management reviews were randomly selected from online pharmacist 
contact lists to participate in the usability testing. The usability test 
was developed from previous usability studies. Participants were 
timed to perform a DBI calculation with the software based on a drug 
regimen from the case studies. A survey was used to rate the interface, 
functionality, clinical applications, and satisfaction of software.
Results: (1) The software has been designed to allow for ease of 
uploading onto a secured, de-identified, password-protected website. 
The user enters patient data and clicks “Calculate DBI” and immedi-
ately receives a report of the DBI with information on the significance 
of the calculation for the patient. (2) Results indicate good agreement 
between the software and manual calculation (Cohen’s Kappa 0.95) 
among the 16/25 drug regimens from patient case studies tested with 
DBI > 0. (3) During usability testing, 90% of respondents were satis-
fied with the software and agreed the content in the software was 
accurate. The usability study also identified that The DBI Calculator 
was considered useful for recognizing sedative and anticholinergic 
medicines in 80% of participants. The average time for participants 
to complete the task was 7 minutes 21 seconds.
Conclusion: We have developed a reliable calculator to report DBI 
in older patients taking multiple medications. Further studies will 
assess application of The DBI Calculator© in clinical settings such 
as pharmacist medication management reviews.
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